Jacques Medioni

Jacques Medioni

Auto-generated profile, based on publicly available information

Jacques Medioni

Centre of Early Clinical Trials in Cancer, Hôpital Européen Georges-Pompidou, Université Paris Cité, Paris, France

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

16 August 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
Maud VelevMaud Velev
Maud Velev
APAlicja Puszkiel
Alicja Puszkiel
Benoit BlanchetBenoit Blanchet
Benoit Blanchet
SPSixtine de Percin
Sixtine de Percin
NDNicolas Delanoy
Nicolas Delanoy
GBGuillaume Beinse
Guillaume Beinse
Factors associated with olaparib toxicity remain unknown in ovarian cancer patients. The large inter-individual variability in olaparib pharmacokinetics could contribute to the onset of early significant adverse events (SAE). We aimed to retrospectively analyze the pharmacokinetic/pharmacodynamic relationship for toxicity in ovarian cancer patients from “real life” data. The clinical endpoint was the onset of SAE (grade III/IV toxicity or dose reduction/discontinuation). Plasma olaparib concentration was assayed using liquid chromatography at any time over the dosing interval. Trough concentrations (CminPred) were estimated using a population pharmacokinetic model. The association between toxicity and clinical characteristics or CminPred was assessed by logistic regression and non-parametric statistical tests. Twenty-seven patients were included, among whom 13 (48%) experienced SAE during the first six months of treatment. Olaparib CminPred was the only covariate significantly associated with increased risk of SAE onset (odds ratio = 1.31, 95%CI = [1.10; 1.57], for each additional 1000 ng/mL). The ROC curve identified a threshold of CminPred = 2500 ng/mL for prediction of SAE onset (sensitivity/specificity 0.62 and 1.00, respectively). This study highlights a significant association between olaparib plasma exposure and SAE onset and identified the threshold of 2500 ng/mL trough concentration as potentially useful to guide dose adjustment in ovarian cancer patients.

1 February 2020 in Journal of Visceral Surgery
Verified
Journal Article
Closed access
MPM. Prudhomme
M. Prudhomme
ALAntoine Legras
Antoine Legras
CDC. Delorme
C. Delorme
TLT. Lansaman
T. Lansaman
MLMichel Lantéri-Minet
Michel Lantéri-Minet
EVE. Viel
E. Viel

1 September 2017 in Contemporary Clinical Trials Communications
Verified
Journal Article
Open access
JMJacques Medioni
Jacques Medioni
MBMara Brizard
Mara Brizard
REReza Elaidi
Reza Elaidi
PRPaul F. Reid
Paul F. Reid
KBKhadija Benlhassan
Khadija Benlhassan
DBDorothy Bray
Dorothy Bray
Crotoxin has a broad antitumor activity but has shown frequent neurotoxic toxicity. To induce tolerance and limit this toxicity, we propose a new design with intra-patient dose escalation. A new Dose Limiting Toxicity definition was used. The concept of Target Ceiling Dose was introduced. Dose Limiting Toxicity was the inability to dose escalate twice. Target Ceiling Dose was the highest planned dose to be administered to a patient and could change for patients along time. Recommended Dose was defined similarly as in a (3 + 3) conventional design. This innovant design was used and the clinical trial is now closed for inclusions. Results will be presented later.

12 December 2003 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
PLP Leuraud
P Leuraud
LTL Taillandier
L Taillandier
LAL Aguirre-Cruz
L Aguirre-Cruz
JMJ Medioni
J Medioni
ECE Crinière
E Crinière
MSM Sanson
M Sanson
In order to develop preclinical models of malignant astrocytomas and oligodendrogliomas, a series of 54 resected gliomas (37 from oligodendroglial lineage and 17 from astrocytic lineage) were xenografted subcutaneously into nude mice. Molecular alterations commonly observed in gliomas subtypes, including LOH 1p and 1q, LOH 19q, LOH 10p and 10q, LOH 9p, TP53 and PTEN mutations, EGFR amplification, CDKN2A homozygous deletion and telomerase reactivation were systematically screened in the original and xenografted tumours. In all, 23 gliomas grew in nude mice. The most anaplastic tumours were selected as shown by pathological and molecular studies of the original tumour as well as shorter survival in patients whose tumours were successfully grafted. Comparison between the two growth profiles showed that 10q LOH and EGFR amplification gave a tumorigenic advantage. With a few exceptions, the genetic pattern was remarkably stable before and after growth in nude mice.These results suggest that subcutaneous xenografts are useful and reproducible models to analyse the molecular profile of malignant astrocytoma and oligodendroglioma. This represents the first step to improve our understanding of the correlations between molecular alterations and response to standard or experimental therapies.

14 February 2025 in The Breast
Verified
Journal Article
Open access
KDK. Debbi
K. Debbi
MBM.A. Benderra
M.A. Benderra
JMJ. Medioni
J. Medioni
CDC. Durdux
C. Durdux
NTN.H. To
N.H. To
YBY. Belkacemi
Y. Belkacemi
Trastuzumab Deruxtecan (T DXD), a new antibody drug conjugate is a new treatment option for 2nd line metastatic breast cancer (MBC) for HER2 + or HER2 low tumors. Palliative or ablative radiotherapy (RT) may be required in patients who are being treated with T-DXd. However there is a lack of evidence regarding the safety profile of combining T-DXd with RT. TENDANCE study aimed to evaluate safety and efficacy of combined T-DXd and RT. This retrospective multicenter study included 54 patients treated concurrently with T-DXd and RT for HER2+ and HER2 low MBC between February 2021 and December 2023. All data were collected from a web-questionnaire, centralized after medical records and validation of the protocol by the local ethical committee. Primary endpoint was the safety of combined therapy. Median age was 60 years. Patients who received T-DXD were further categorized into HER2+ (40.7 %), HER2 low/hormonal receptors HR+ (40.8 %) or HER2 low/HR- (18.5 %). In the HER2+ patients, T-DXd was administered as 2nd (18.2 %) or 3rd (31.8 %) or 4th (50 %) line therapy. RT was delivered using palliative (72.2 %) or ablative doses (27.8 %). Indications consisted mostly of palliative bone irradiation (46.3 %) and stereotactic radiosurgery (SRS) (25.9 %). With the median follow-up of 9 months, 22.2 % of patients had a complete response and 77.8 % had either a partial response or stable disease. Grade 1 or 2 asthenia was observed in 51.8 % of patients, while only 16.6 % experienced other grade 1 or 2 adverse effects. There was no T-DXd therapy discontinuation related to RT. To our knowledge, TENDANCE is the largest study evaluating concurrent T-DXd and RT. This preliminary report suggests the feasibility of the combination of RT and T-DXd with manageable toxicity rate. Longer follow-up and further prospective studies are required to confirm these results.